Geron Corp - Company Profile

Powered by

All the data and insights you need on Geron Corp in one report.

$ $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date Geron Corp Strategy Report

  • Understand Geron Corp position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Geron Corp: Overview

Select Item

Geron Corp (Geron) is a late-stage clinical biopharmaceutical company that focuses on the development and commercialization of imetelstat, a first-in-class telomerase inhibitor in hematologic myeloid malignancies. It’s clinical studies include IMerge, a Phase 2 trial in lower risk myelodysplastic syndromes; and IMbark, a Phase 2 clinical trial in intermediate or high-risk myelofibrosis. Imetelstat received Fast Track designation from the US FDA to treat patients with transfusion-dependent anemia due to lower or intermediate-risk myelodysplastic syndromes (MDS) and patients with intermediate or high-risk myelofibrosis (MF). The company utilizes core expertise in telomerase and telomere biology and its proprietary nucleic acid chemistry for the development of imetelstat. Geron is headquartered in Menlo Park, California, the US.

 Gain a 360-degree view of Geron Corp and make more informed decisions for your business Gain a 360-degree view of Geron Corp and make more informed decisions for your business Find out more
Headquarters United States of America
Address 919 East Hillsdale Boulevard, Suite 250, Foster City, California, 94404
Website www.geron.com
Telephone 1 650 4737700
No of Employees 141
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange GERN (NASD)
Revenue (2022) $237,000 -60.2% (2022 vs 2021)
EPS XYZ
Net Income (2022) XYZ -29.8% (2022 vs 2021)
Market Cap* $2.2B
Net Profit Margin (2023) XYZ -226.3% (2022 vs 2021)
* As of and is in US$
View Geron Corp financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Geron Corp premium industry data and analytics

20+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Geron Corp’s relevant decision makers and contact details.

20+

Clinical Trials

Determine Geron Corp go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

20+

Catalyst Calendar

Proactively evaluate Geron Corp’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

14+

Pipeline Drugs

Identify which of Geron Corp’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

5

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

1

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

Products and Services

Products
Pipeline
Imetelstat-Telomerase Inhibitor
Understand Geron Corp portfolio and identify potential areas for collaboration Understand Geron Corp portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2023 Official Trials/Tests In April, the company announced positive top-line results of its product Imetelstat from IMerge Phase 3 Trial.
2021 Official Trials/Tests In October, the company announced the completion of patient enrollment in IMerge Phase 3 Clinical Trial in Myelodysplastic Syndromes.
2021 Contracts/Agreements In October, the company’s Imetelstat entered into New Innovative Licensing and Access Pathway in United Kingdom.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters Geron Corp Amgen Inc Genmab AS FibroGen Inc Acceleron Pharma Inc
Headquarters United States of America United States of America Denmark United States of America United States of America
City Foster City Thousand Oaks Koebenhavn V San Francisco Cambridge
State/Province California California - California Massachusetts
No. of Employees 141 26,700 2,204 486 312
Entity Type Public Public Public Public Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
John A. Scarlett, M.D. President; Chairman; Director; Chief Executive Officer Executive Board 2018 72
Michelle Robertson Treasurer; Executive Vice President; Chief Financial Officer Senior Management 2023 -
Andrew J. Grethlein, Ph.D. Chief Operating Officer; Executive Vice President Senior Management 2019 58
Stephen N. Rosenfield Secretary; Chief Legal Officer; Executive Vice President Senior Management 2019 73
Faye Feller, M.D Executive Vice President; Chief Medical Officer Senior Management 2022 40
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Geron Corp key executives to enhance your sales strategy Gain insight into Geron Corp key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward